Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: A meta-analysis

Frontiers in Pharmacology

Volumn 8, Issue OCT, 2017, Pages

  Wang, Peng Fei ^a   Chen, Yang ^a,b   Song, Si Ying ^a   Wang, Ting Jian ^a   Ji, Wen Jun ^c   Li, Shou Wei ^a   Liu, Ning ^a   Yan, Chang Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti PD 1 antibodies; Immune related adverse events; Immunotherapy; Nivolumab; Oncology

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BMS 936559; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ADRENAL INSUFFICIENCY; ANUS CARCINOMA; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER PATIENT; COLITIS; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG INFILTRATE; MACULOPAPULAR RASH; MELANOMA; MERKEL CELL CARCINOMA; META ANALYSIS; MULTIPLE CANCER; NEPHRITIS; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREATITIS; PERITONEUM CANCER; PNEUMONIA; PROSTATE CANCER; PRURITUS; RASH; RENAL CELL CARCINOMA; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; STOMACH CANCER; SYSTEMATIC REVIEW; THYROIDITIS; TRANSITIONAL CELL CARCINOMA; VITILIGO;

EID: 85031793563     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00730     Document Type: Article

References (64)

1. Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., et al. (2016). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67-76. doi: 10.1016/S0140-6736(16)32455-2
2. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., et al. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015-1026. doi: 10.1056/NEJMoa1613683
3. Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E., and Schaeverbeke, T. (2015). Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13:211. doi: 10.1186/s12916-015-0455-8
4. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D., Steins, M., Ready, N., et al. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Eng. J. Med. 373, 1627-1639. doi: 10.1056/NEJMoa1507643
5. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175. doi: 10.1200/JCO.2009.26.7609
6. Brahmer, J., Reckamp, K., Baas, P., Crinò, L., Eberhardt, W., Poddubskaya, E., et al. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Eng. J. Med. 373, 123-135. doi: 10.1056/NEJMoa1504627
7. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465. doi: 10.1056/NEJMoa1200694
8. Callahan, M. K., Postow, M. A., and Wolchok, J. D. (2016). Targeting T Cell co-receptors for cancer therapy. Immunity 44, 1069-1078. doi: 10.1016/j.immuni.2016.04.023
9. Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., et al. (2016). Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann. Oncol. 27, 1291-1298. doi: 10.1093/annonc/mdw174
10. Chen, T. W., Razak, A. R., Bedard, P. L., Siu, L. L., and Hansen, A. R. (2015). A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann. Oncol. 26, 1824-1829. doi: 10.1093/annonc/mdv182
11. Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., et al. (2016). Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461-5471. doi: 10.1158/1078-0432.CCR-15-2839
12. Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., et al. (2017). Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 8, 8910-8920. doi: 10.18632/oncotarget.13315
13. Eigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grunwald, V., et al. (2016). Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat. Rev. 45, 7-18. doi: 10.1016/j.ctrv.2016.02.003
14. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837-1846. doi: 10.1016/S0140-6736(16)00587-0
15. Ferris, R. L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., et al. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867. doi: 10.1056/NEJMoa1602252
16. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028. doi: 10.1056/NEJMoa1501824
17. Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., et al. (2015). Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004-2012. doi: 10.1200/JCO.2014.58.3708
18. Gettinger, S., Rizvi, N., Chow, L., Borghaei, H., Brahmer, J., Ready, N., et al. (2016). Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 2980-2987. doi: 10.1200/JCO.2016.66.9929
19. Gibney, G. T., Weiner, L. M., and Atkins, M. B. (2016). Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542-e551. doi: 10.1016/S1470-2045(16)30406-5
20. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., et al. (2015). Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015-4022. doi: 10.1200/JCO.2015.62.3397
21. Herbst, R., Baas, P., Kim, D., Felip, E., Pérez-Gracia, J., Han, J., et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550. doi: 10.1016/S0140-6736(15)01281-7
22. Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi: 10.1136/bmj.d5928
23. Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., et al. (2016). Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152, 45-51. doi: 10.1001/jamadermatol.2015.2707
24. Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., et al. (2017). Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 168:542. doi: 10.1016/j.cell.2017.01.010
25. Hui, R., Garon, E. B., Goldman, J. W., Leighl, N. B., Hellmann, M. D., Patnaik, A., et al. (2017). Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann. Oncol. 28, 874-881. doi: 10.1093/annonc/mdx008
26. Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., et al. (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374-1385. doi: 10.1016/S1470-2045(16)30364-3
27. Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., and Chandra, A. B. (2017). Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8:49. doi: 10.3389/fphar.2017.00049
28. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Eng. J. Med. 373, 23-34. doi: 10.1056/NEJMoa1504030
29. Leach, D. R., Krummel, M. F., and Allison, J. P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736. doi: 10.1126/science.271.5256.1734
30. Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., et al. (2016). Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J. Clin. Oncol. 34, 2698-2704. doi: 10.1200/JCO.2015.65.9789
31. Marrone, K. A., Ying, W., and Naidoo, J. (2016). Immune-related adverse events from immune checkpoint inhibitors. Clin. Pharmacol. Ther. 100, 242-251. doi: 10.1002/cpt.394
32. Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., et al. (2016). Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119-3125. doi: 10.1200/JCO.2016.67.9761
33. McDermott, D. F., Drake, C. G., Sznol, M., Choueiri, T. K., Powderly, J. D., Smith, D. C., et al. (2015). Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33, 2013-2020. doi: 10.1200/JCO.2014.58.1041
34. McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., et al. (2016). Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J. Clin. Oncol. 34, 833-842. doi: 10.1200/JCO.2015.63.7421
35. Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy comes of age. Nat. Clin. Pract. Oncol. 2, 480-489. doi: 10.1038/nature10673
36. Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. (2016). Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139-148. doi: 10.1016/j.ejca.2015.11.016
37. Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., et al. (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 446-453. doi: 10.1016/S1470-2045(17)30104-3
38. Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., et al. (2015). Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813. doi: 10.1056/NEJMoa1510665
39. Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., et al. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17, 717-726. doi: 10.1016/S1470-2045(16)00175-3
40. Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460-2467. doi: 10.1200/JCO.2015.64.8931
41. Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H., and Hodi, F. S. (2016). Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1607-1616. doi: 10.1001/jamaoncol.2016.2453
42. Nishino, M., Sholl, L. M., Hodi, F. S., Hatabu, H., and Ramaiya, N. H. (2015). Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N. Engl. J. Med. 373, 288-290. doi: 10.1056/NEJMc1505197
43. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264. doi: 10.1038/nrc3239
44. Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., et al. (2015). Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286-4293. doi: 10.1158/1078-0432.CCR-14-2607
45. Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q., Juco, J., et al. (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 18, 212-220. doi: 10.1016/S1470-2045(17)30007-4
46. Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A., et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 375, 1823-1833. doi: 10.1056/NEJMoa1606774
47. Ribas, A., Hamid, O., Daud, A., Hodi, F., Wolchok, J., Kefford, R., et al. (2016). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA 315, 1600-1609. doi: 10.1001/jama.2016.4059
48. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908-918. doi: 10.1016/S1470-2045(15)00083-2
49. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255-265. doi: 10.1016/S0140-6736(16)32517-X
50. Rizvi, N. A., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265. doi: 10.1016/S1470-2045(15)70054-9
51. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. (2015a). Nivolumab in previously untreated melanoma without BRAF mutation. New Eng. J. Med. 372, 311-319. doi: 10.1056/NEJMoa1412082
52. Robert, C., Ribas, A., Wolchok, J., Hodi, F., Hamid, O., Kefford, R., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109-1117. doi: 10.1016/S0140-6736(14)60958-2
53. Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., et al. (2015b). Pembrolizumab versus ipilimumab in advanced melanoma. N. Eng. J. Med. 372, 2521-2532. doi: 10.1056/NEJMoa1503093
54. Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., et al. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920. doi: 10.1016/S0140-6736(16)00561-4
55. Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., et al. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956-965. doi: 10.1016/S1470-2045(16)30066-3
56. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., et al. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312-322. doi: 10.1016/S1470-2045(17)30065-7
57. Shimizu, T., Seto, T., Hirai, F., Takenoyama, M., Nosaki, K., Tsurutani, J., et al. (2016). Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest. New Drugs 34, 347-354. doi: 10.1007/s10637-016-0347-6
58. Tie, Y., Ma, X., Zhu, C., Mao, Y., Shen, K., Wei, X., et al. (2017). Safety and efficacy of nivolumab in the treatment of cancers: a meta-analysis of 27 prospective clinical trials. Int. J. Cancer 140, 948-958. doi: 10.1002/ijc.30501
59. Topalian, S., Hodi, F., Brahmer, J., Gettinger, S., Smith, D., McDermott, D., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Eng. J. Med. 366, 2443-2454. doi: 10.1056/NEJMoa1200690
60. Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030. doi: 10.1200/JCO.2013.53.0105
61. Topalian, S. L., Taube, J. M., Anders, R. A., and Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275-287. doi: 10.1038/nrc.2016.36
62. Weber, J., D'Angelo, S., Minor, D., Hodi, F., Gutzmer, R., Neyns, B., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet. Oncol. 16, 375-384. doi: 10.1016/S1470-2045(15)70076-8
63. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., et al. (2016). Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol. Res. 4, 345-353. doi: 10.1158/2326-6066.CIR-15-0193
64. Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., et al. (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17, 1283-1294. doi: 10.1016/S1470-2045(16)30167-X